BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25561510)

  • 1. Advances in anticancer immunotoxin therapy.
    Alewine C; Hassan R; Pastan I
    Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer Immunotoxins, Challenges, and Approaches.
    Dashtiahangar M; Rahbarnia L; Farajnia S; Salmaninejad A; Shabgah AG; Ghasemali S
    Curr Pharm Des; 2021; 27(7):932-941. PubMed ID: 33023437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxin therapy of cancer.
    Pastan I; Hassan R; Fitzgerald DJ; Kreitman RJ
    Nat Rev Cancer; 2006 Jul; 6(7):559-65. PubMed ID: 16794638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotoxin: A new tool for cancer therapy.
    Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
    Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.
    Behdani M; Zeinali S; Karimipour M; Khanahmad H; Schoonooghe S; Aslemarz A; Seyed N; Moazami-Godarzi R; Baniahmad F; Habibi-Anbouhi M; Hassanzadeh-Ghassabeh G; Muyldermans S
    N Biotechnol; 2013 Jan; 30(2):205-9. PubMed ID: 23031816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxins: the role of the toxin.
    Antignani A; Fitzgerald D
    Toxins (Basel); 2013 Aug; 5(8):1486-502. PubMed ID: 23965432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial Toxins for Cancer Therapy.
    Zahaf NI; Schmidt G
    Toxins (Basel); 2017 Jul; 9(8):. PubMed ID: 28788054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
    Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
    Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxins.
    Kreitman RJ
    Expert Opin Pharmacother; 2000 Sep; 1(6):1117-29. PubMed ID: 11249483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxin-labeled monoclonal antibodies.
    Kreitman RJ
    Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to Immunotoxins Containing
    Dieffenbach M; Pastan I
    Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32630017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of anticancer immunotoxins.
    Choudhary S; Mathew M; Verma RS
    Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of Single-Domain Antibody-Based Recombinant Immunotoxins.
    Fleming BD; Ho M
    Methods Mol Biol; 2022; 2446():489-512. PubMed ID: 35157290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxin conjugate therapy of cancer.
    Wong L; Suh DY; Frankel AE
    Semin Oncol; 2005 Dec; 32(6):591-5. PubMed ID: 16338425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
    Wenning LA; Murphy RM
    Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.